Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
The New England Journal of Medicine|July 22, 2010
Early versus standard antiretroviral therapy for HIV-infected adults in HaitiPatrice Severe, Marc Antoine Jean Juste, Alex Ambroise, et al.
Lancet (London, England)|July 20, 2002
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesMatthias Egger, Margaret May, Geneviève Chêne, et al.
Nature Medicine|October 6, 2005
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Gerd Fätkenheuer, Anton L Pozniak, Margaret A Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2017
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mLBabafemi O Taiwo, Lu Zheng, Andrei Stefanescu, et al.
The Journal of Infectious Diseases|February 14, 2008
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjectsDaniel R Kuritzkes, Christina M Lalama, Heather J Ribaudo, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2021
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305Todd T Brown, Krista Yuhas, Kenneth H Mayer, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Pageof 21